NIH study finds omalizumab relieves seasonal asthma attacks in youth – 3
Narrator: This is NIH Health Matters. I’m Joe Balintfy. A recent study has released three key asthma findings. One is that the drug omalizumab relieves asthma symptoms in inner-city youth. Dr. Alkis Togias at the National Institute of Allergy and Infectious Diseases says the second finding shows an almost complete elimination of surges during peak asthma seasons.
Dr. Togias: And the third finding was that we identified a sub-population of these children that appeared extremely responsive to this medication. And that was a population of children who were allergic to cockroach, but were also exposed to high levels of cockroach in their homes.
Narrator: For details on the study and asthma research, visit www.niaid.nih.gov. Health Matters is produced by the National Institutes of Health, part of the U.S. Department of Health and Human Services.
About NIH Audio
NIH Audio offers free audio news programs from the National Institutes of Health, your reliable source for health information.
All NIH Audio content is in the public domain and can be used without charge or restriction provided that it is not used to misrepresent our agency nor used to suggest we endorse any private organization, product, or service.
NIH Audio is a service of the Office of Communications & Public Liaison.